Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 16/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24973975 | 1.00 | DRD4 (0.46) | DRD4SIGMAR1TMEM97DRD3DRD5 | |
| SCHEMBL24973996 | 0.84 | DRD4 (0.44) | DRD4SIGMAR1TMEM97DRD3DRD5 | |
| SCHEMBL26933298 | 0.83 | GRM2 (0.44) | DRD4SIGMAR1TMEM97DRD3DRD5 | |
| SCHEMBL26933291 | 0.83 | GRM2 (0.44) | DRD4SIGMAR1TMEM97DRD3DRD5 | |
| SCHEMBL24973824 | 0.83 | MAOB (0.36) | DRD4SIGMAR1TMEM97MAOB | |
| SCHEMBL21503609 | 0.83 | DRD4 (0.44) | DRD4SIGMAR1TMEM97DRD3DRD5 | |
| SCHEMBL24973973 | 0.83 | DRD4 (0.44) | DRD4SIGMAR1TMEM97DRD3DRD5 | |
| Hydrochloric Acid SCHEMBL21491496 | 0.82 | GRM2 (0.43) | DRD4SIGMAR1TMEM97DRD3DRD5 | |
| Hydrochloric Acid SCHEMBL21491497 | 0.82 | GRM2 (0.43) | DRD4SIGMAR1TMEM97DRD3DRD5 | |
| Hydrochloric Acid SCHEMBL30636343 | 0.82 | GRM2 (0.43) | DRD4SIGMAR1TMEM97DRD3DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | DRD4 4100/4885SIGMAR1 4583/4885TMEM97 4626/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | DRD4 4100/4885SIGMAR1 4583/4885TMEM97 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.